Lipoprotein(a) is an LDL-like particle in which one apolipoprotein B100 molecule is covalently linked to apolipoprotein(a) (Erqou et al., 2009). Its concentration is largely genetically set (by the LPA gene), stable within a person over years, and not meaningfully moved by the diet/activity/weight levers this wiki is built around. So it is not itself a modifiable exposure. It earns a page for a different reason: it is a baseline-risk stratifier that changes the absolute payoff of the lipid-lowering levers a person can pull -> see the decision hook below.
The observational association (what ERFC established)
The Emerging Risk Factors Collaboration pooled individual participant data on 126 634 people in 36 prospective studies, over 1.3 million person-years, having excluded anyone with known CHD or stroke at baseline (Erqou et al., 2009). Higher usual Lp(a) tracked higher vascular risk, and the association was broadly continuous in shape (no threshold located; a potentially curvilinear rise at the high end is noted, not resolved).
Effect sizes are stated per 3.5-fold higher usual Lp(a) concentration (ie, per 1 SD), after regression-dilution correction:
| Outcome | Adjusted risk ratio per 1-SD (3.5-fold) higher usual Lp(a) | 95% CI |
|---|---|---|
| CHD (age/sex-adjusted) | 1.16 | 1.11-1.22 |
| CHD (further adj. for lipids + conventional risk factors) | 1.13 | 1.09-1.18 |
| Ischemic stroke | 1.10 | 1.02-1.18 |
| Nonvascular mortality (aggregate) | 1.01 | 0.98-1.05 |
| Cancer deaths | 1.00 | 0.97-1.04 |
| Nonvascular deaths other than cancer | 1.00 | 0.95-1.06 |
Two features carry the decision, not the point estimates:
- The effect is modest and vascular-specific. ERFC’s own summary: «Under a wide range of circumstances, there are continuous, independent, and modest associations of Lp(a) concentration with risk of CHD and stroke that appear exclusive to vascular outcomes.» (Erqou et al., 2009) The three nonvascular rows are flat (CIs straddle 1.00) — the risk is confined to vascular disease, not a general frailty marker.
- It survives adjustment for the standard lipids. The CHD RR falls only from 1.16 to 1.13 after adjusting for non-HDL cholesterol and other conventional risk factors — Lp(a) adds risk information beyond a standard lipid panel. Overall it is only about one-quarter as strong as non-HDL cholesterol for CHD (Erqou et al., 2009).
The decision hook — a route-(a) baseline-risk multiplier
Because Lp(a) is essentially unmodifiable by lifestyle, its value is not a new lever but a baseline-risk shift (transportability route (a): absolute benefit scales with baseline risk even when the relative effect of the available intervention is unchanged, with no subgroup claim required). ERFC states the consequence directly: because the Lp(a)-CHD association is similar at every level of non-HDL cholesterol, «the absolute benefits of cholesterol lowering should be greater if Lp(a) concentration is high (or when absolute risk is high for some other reason).» (Erqou et al., 2009)
So the decision-change is: a known-high Lp(a) up-weights the apoB/LDL-lowering lever LDL ApoB and Cumulative Exposure — the same diet, and the drug comparators (statins, ezetimibe), buy more absolute risk reduction in a person whose absolute risk is raised by high Lp(a). It does not tell that person to do anything Lp(a)-specific with lifestyle, because there is nothing lifestyle does to Lp(a). This keeps Lp(a) firmly a Layer-2 prognostic input, not a Layer-1 exposure of its own.
The observational-vs-causal gap (a named G-gap)
ERFC is an observational IPD meta-analysis, so its RRs are risk associations, corrected for regression dilution but still open to residual confounding. The causal magnitude is a separate question this source cannot answer, and it flags the direction itself: the LPA-gene variant studies, taken with these findings, are «consistent with the existence of a causal relationship» and «interventions capable of much more powerful and specific Lp(a) lowering than currently available may be required to demonstrate any vascular benefits in randomized trials.» (Erqou et al., 2009)
- Directional inference, not held evidence. Lp(a) is the textbook case where the genetically-instrumented (Mendelian-randomization) effect is expected to exceed the observational association, because a lifelong genetic exposure is unconfounded and undiluted by within-person variation. The wiki does not yet hold that evidence, so this remains a directional expectation, marked as inference.
- The causal leg — Mendelian randomization and any Lp(a)-lowering outcome trial — is not held. — the genetic evidence that would convert this association into a causal effect estimate and confirm whether the true effect is larger than 1.13/1-SD.
Vascular-specificity — a companion contrast, NOT independent corroboration
Lp(a)‘s confinement to vascular outcomes (null for cancer and other nonvascular death) contrasts with the broader marker C-reactive protein. That contrast is a useful specificity note, but it comes from the same collaboration (the ERFC CRP IPD, erfc2010crp), so it is not independent (type-E) backing — a shared body/analysis pipeline defeats independence by construction. Treat it as a same-source companion observation, not as convergent evidence . -> Surrogate Outcomes (Lp(a) as a risk marker vs a steering target).
What this page does NOT establish
- It is a single-source (provisional) opener for a new
lipoprotein-acluster; the observational association is gold-tier IPD, but the causal effect, the shape at high concentrations, and any Lp(a)-lowering treatment benefit are open (henceconfidence: medium). - The loop is open. No Lp(a)-lowering intervention is shown here to reduce events; the page establishes a prognostic association and a baseline-risk implication, not a validated treatment target.